The TARGET-IV NA Trial: Multicenter Randomized Assessment of the Firehawk® rapamycin TARGET eluting cobalt chromium coronary stent system –North American Trial

  • sponsor
    Shanghai MicroPort Medical (Group) Co., Ltd.
Updated on 18 October 2021
heart disease
unstable angina
coronary disease


The aim of this trial is to demonstrate the clinical non-inferiority of the Firehawk® rapamycin eluting stent system in comparison to currently approved 2nd generation DES for the treatment of subjects with ischemic heart disease (NSTEMI, recent STEMI), unstable angina, and stable coronary disease), with atherosclerotic target lesion(s) in coronary arteries with visually estimated reference vessel diameters ≥2.25 mm and ≤4.0 mm.


  • Condition: Coronary Artery Disease
  • Device: Firehawk® stent system
  • Clinical Trial Identifier: NCT04562532

Condition Heart Disease, Coronary Disease, Heart disease, Stent, Cardiac Disease, Coronary Artery Disease, Myocardial Ischemia, Heart Diseases, Myocardial Ischemia
Clinical Study IdentifierTX276528
SponsorShanghai MicroPort Medical (Group) Co., Ltd.
Last Modified on18 October 2021


Yes No Not Sure

Inclusion Criteria

Age ≥ 18 years
Patients with an indication for PCI including angina (stable or unstable), silent ischemia, NSTEMI, or recent STEMI (STEMI >24 hours and in whom enzyme levels have peaked)
Angiographic inclusion criteria
1. Target lesion(s) must be located in a native coronary artery with visually estimated diameter of ≥2.25 mm to ≤4.0 mm and up to 44 mm in length
2. Complex lesions are allowed including calcified lesions, ostial lesions, tortuous lesions, and protected left main lesions
3. Overlapping stents are allowed

Exclusion Criteria

STEMI within 24 hours of initial time of presentation to the first treating hospital, whether at a transfer facility or the study hospital or in whom enzyme levels (either CK-MB or Troponin) have not peaked
PCI within the 24 hours preceding the baseline procedure
History of stent thrombosis
Cardiogenic shock or requiring pressors or hemodynamic support, including IABP
Known LVEF <30%
Calculated creatinine clearance <30 mL/min using Cockcroft-Gault equation
Hemoglobin <10 g/dL., platelet count <100,000 cells/mm3 or >700,000 cells/mm3 and white blood cell count <3,000 cells/mm3
Other serious medical illness with a life-expectancy < 24 months (e.g., cancer, severe heart failure, severe lung disease)
Intention to become pregnant within 12 months (women of child-bearing potential who are sexually active must agree to use contraceptives from the time of enrollment through 12 months post-procedure)
Angiographic Exclusion Criteria
1. Unprotected left main interventions
2. Bifurcation lesions with intended dual stent implantations
3. DES restenotic lesions and Lesion with intended ≥ 3 stent implantation
4. Any lesion in the target vessel that is likely to require PCI within 12 months
5. Stent lengths >36mm for diameters 2.0 mm and 2.25 mm (i.e., very long thin stents)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note